Getting ahead of neuropathic pain
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
by Marybeth Burke – Some of the most essential mainstays in cancer treatment drugs for adults and children are in short supply, Michael Link, M.D., president of the… read more.
by Edel O’Connell – Report on poster presented at the ICS Annual Meeting
by Edel O’Connell reporting on the presentation by Professor Alain Carpentier.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – Over 1,000 small and medium enterprises (SMEs) have now registered with European Medicines Agency SME office. The… read more.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – The CHMP has recommended the first medical treatment for the removal of eschar from severe burn wounds.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – The EMA has given the green light for the first medicine specifically for irritable bowel syndrome (IBS)… read more.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – There’s a new man at the helm of the European Medicine Agency’s most influential committee: Dr Tomas… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Adalimumab appears to be effective in maintaining remission among some pediatric patients with Crohn’s disease.